Ascending Paralysis: Urgent Evaluation and Management
In an adult with rapid-onset ascending paralysis, immediately consider Guillain-Barré syndrome (GBS) as the primary diagnosis and initiate urgent evaluation for respiratory failure while simultaneously pursuing diagnostic confirmation and immunotherapy. 1
Immediate Recognition and Assessment
GBS should be suspected in any patient presenting with rapidly progressive bilateral leg and/or arm weakness without CNS involvement 1. The classic presentation includes:
- Distal paresthesias or sensory loss followed by weakness starting in legs, ascending to arms and cranial muscles
- Decreased or absent reflexes (present in most patients at presentation, nearly all at nadir)
- Progression to maximum disability within 2 weeks (if progression occurs within 24 hours or after 4 weeks, strongly consider alternative diagnoses) 1
Critical pitfall: Do not dismiss atypical presentations. GBS can present with asymmetric weakness, predominantly proximal or distal patterns, severe diffuse pain preceding weakness, or isolated cranial nerve dysfunction 1.
Urgent Respiratory and Autonomic Monitoring
Respiratory failure occurs in 20% of GBS patients and requires mechanical ventilation 1. Immediately assess:
- Vital capacity monitoring (most critical parameter for detecting impending respiratory failure) 2
- Swallowing and coughing ability (bulbar dysfunction)
- Continuous ECG monitoring for cardiac arrhythmias from dysautonomia 1, 2
- Blood pressure stability (autonomic dysfunction is common) 1
Two-thirds of GBS deaths occur during the recovery phase from cardiovascular and respiratory dysfunction, so maintain vigilance even after initial stabilization 1.
Diagnostic Confirmation
Pursue these investigations while preparing for treatment:
- Electrophysiological studies: Confirm peripheral nerve dysfunction and distinguish between AIDP, AMAN, and AMSAN subtypes 1
- CSF analysis: Classic finding is cytoalbuminologic dissociation (elevated protein with normal cell count), though this may not be present early 1, 3
- Rule out alternative diagnoses including spinal cord pathology, myasthenia gravis, hypokalemic paralysis, and vascular causes 4, 5
Definitive Treatment
Initiate immunotherapy immediately once GBS is strongly suspected clinically—do not delay for diagnostic confirmation 3. The two equally effective options are:
Intravenous Immunoglobulin (IVIG): 0.4 g/kg daily for 5 consecutive days 1
- Preferred over plasma exchange due to similar efficacy but greater convenience 2
Plasma Exchange: 200-250 mL/kg over 5 sessions 1
- Alternative when IVIG unavailable or contraindicated
Important caveat: Corticosteroids are NOT helpful in GBS 2. Approximately 40% of patients show insufficient response to initial treatment, but this does not necessarily indicate treatment failure—progression might have been worse without therapy 1.
Managing Treatment-Related Fluctuations
6-10% of patients experience treatment-related fluctuations (TRFs): clinical deterioration within 2 months after initial improvement or stabilization 1. When TRFs occur:
- Repeat the full course of IVIG or plasma exchange (common practice, though evidence is limited) 1
- Distinguish from acute-onset CIDP if ≥3 TRFs occur or deterioration happens ≥8 weeks after onset 1
ICU Admission Criteria
Transfer to ICU if any of the following are present:
- Rapidly progressive weakness
- Bulbar dysfunction affecting swallowing
- Declining vital capacity
- Autonomic instability (arrhythmias, blood pressure fluctuations) 1
Prognosis
60-80% of patients walk independently at 6 months with treatment 1. Recovery can continue for more than 3 years after onset, and recurrence is rare (2-5%) 1. Calculate the modified Erasmus GBS Outcome Score (mEGOS) on admission to predict individual outcomes 1.
The key to preventing mortality and severe morbidity is early recognition, immediate respiratory monitoring, and prompt initiation of immunotherapy without waiting for complete diagnostic confirmation.